Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Article
Change log
Authors
Description
Keywords
Humans, Breast Neoplasms, Receptor, erbB-2, Treatment Outcome, Chemotherapy, Adjuvant, Perception, Female, Cardiotoxicity, Surveys and Questionnaires, Trastuzumab, Antineoplastic Agents, Immunological
Journal Title
BMC cancer
Conference Name
Journal ISSN
1471-2407
1471-2407
1471-2407
Volume Title
18
Publisher
Publisher DOI
Sponsorship
NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) (HTA/06/303/98)